![]()
NeuroPace Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into NeuroPace (NPCE)
PR Newswire
NEW YORK, Nov. 16, 2026
NeuroPace raised its 2026 revenue outlook on August 11, 2026, then cut it to $91-$92 million one quarter later. The investigation concerns potential federal securities law violations tied to those statements.
NEW YORK, Nov. 16, 2026 /PRNewswire/ — NeuroPace, Inc. (NASDAQ: NPCE) shares fell over 37% on November 13, 2026, after the Company cut its full-year 2026 revenue guidance to $91-$92 million, one quarter after management raised that same outlook to $99.5-$101.5 million. If you lost money on NeuroPace stock, you are encouraged to submit your loss information now or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
On the August 11, 2026 second-quarter call, Chief Financial Officer Patrick Williams told investors: “We are increasing full-year total revenue guidance to a range of $99.5 million to $101.5 million, compared to our previous range of $99 million to $101 million.” He added: “We expect our third quarter RNS revenue growth to be similar to our first half RNS growth rate of approximately 20% year-over-year.” On the same call, Chief Executive Officer Joel Becker cited “continued momentum in the core RNS business and disciplined execution across the organization.”
In its third-quarter report, NeuroPace disclosed revenue of $23.1 million. Total revenue declined 1.1% year over year. Management attributed the shortfall to three causes: a sales-force restructuring, disruptions at several large customer accounts, and the continuing effect of exiting the SEEG distribution business. Levi & Korsinsky is investigating whether NeuroPace may not have adequately disclosed these developments and whether potential securities law violations occurred.
Shareholders who lost money on NPCE can request a free review of their NeuroPace losses or call (212) 363-7500.
WHY LEVI & KORSINSKY — Ranked in ISS Securities Class Action Services’ Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered billions of dollars for investors.
Frequently Asked Questions About the NPCE Investigation
Q: Who is eligible to participate in the NPCE investigation? A: Investors who purchased NPCE stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether NeuroPace made materially false or misleading statements regarding its full-year 2026 revenue guidance and third-quarter growth expectations. When the Company disclosed third-quarter revenue of $23.1 million and cut full-year guidance to $91-$92 million, the stock price declined sharply.
Q: When did NeuroPace allegedly mislead investors? A: The investigation concerns statements made before NeuroPace’s November 2026 guidance reduction, including statements on the Company’s August 11, 2026 earnings call, that allegedly caused investors to purchase securities at inflated prices.
Q: What do NPCE investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my NPCE shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought NPCE and sold at a loss may still participate in the investigation.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.
Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neuropace-investigation-notice-levi–korsinsky-notifies-investors-of-pending-investigation-into-neuropace-npce-302940943.html
SOURCE Levi & Korsinsky, LLP
